With just 50 reps to Takeda's 900, Vivus' Qsymia beats Contrave on Q3 sales

Takeda has 900 reps behind Orexigen's ($OREX) Contrave--but is that investment worth it? Maybe not, RBC Capital Markets' Simos Simeonidis suggested recently in a note to investors. Vivus' ($VVUS) Qsymia--with just 50 reps supporting the product--hauled in $14 million in Q3 revenue, compared with just $12.8 million for Contrave. More

Read more on